Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen Biopharma, Inc. (RGBP) is a biotechnology innovator advancing small molecule and RNA-based therapies for cancer and autoimmune diseases. This dedicated news hub provides investors and researchers with centralized access to official updates shaping the company's scientific progress.
Discover timely press releases detailing preclinical milestones, regulatory developments, and strategic partnerships in immunotherapy. Our curated collection includes updates on RNA therapeutic advancements, clinical trial preparations, and patent filings – all essential for understanding RGBP's position in competitive biopharma markets.
Key content categories cover research breakthroughs, executive leadership announcements, and collaboration agreements with academic institutions. Bookmark this page to efficiently track developments in immune cell activation technologies and emerging treatment modalities without promotional bias.
Regen BioPharma (RGBP) has provided updates on its planned Phase 1 clinical trial for HemaXellerate™, a stem cell-derived therapy that received FDA clearance. The therapy aims to stimulate bone marrow regeneration, initially targeting aplastic anemia with potential expansion into chemotherapy-induced bone marrow suppression. The company has partnered with a specialized CRO to conduct the trial, which is expected to complete within 12-14 months. The targeted market for chemotherapy-induced bone marrow suppression is valued at over $1 billion annually.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on September 25, 2024, at 4:00 PM Eastern Time. The company, which focuses on developing cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, invites investors, advisors, and analysts to attend this interactive online event.
CEO Dr. David Koos will lead the presentation, providing updates on fiscal and scientific goals, progress on current programs, and the timeline for the anticipated HemaXellerate clinical phase I. Attendees will have the opportunity to ask questions in real-time during the 10-minute presentation.
Interested parties can register for the event through the provided link. An archived webcast will be available on EmergingGrowth.com for those unable to attend live.
Regen BioPharma, Inc. is set to present at the Emerging Growth Conference on May 9, 2024, offering shareholders and investors insights into its Phase 1 clinical study-ready HemaXellerate and preclinical DuraCAR programs. The event aims to provide real-time interaction with the CEO, Dr. David Koos, enabling attendees to ask questions and stay updated on the company's advancements in biotechnology.
FAQ
What is the current stock price of Regen Biopharma (RGBP)?
What is the market cap of Regen Biopharma (RGBP)?
